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Introduction

Characterization of freeze-dried formulation
• Drug Content

Fig 3(a) shows that the drug is crystalline in nature whereas 3(b) shows that the
freeze-dried formulation is amorphous

• Thermogravimetric Analysis
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• Particle Size Determination • Powder Flow Study
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• Accelerated Stability Study

Intensity (cps)
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Results

500

500

Drug yield

0

0

Drug yield:
Fig 4 (a): Pure efavirenz drug
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Fig 1: Calibration curve
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Table: 1 Drug content
Batch 1

Batch 2

Batch 3

Average

98.4%
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Fig 4 (b): Freeze-dried powder

The angle of repose was determined to understand the
flow of the freeze-dried powder. It was calculated using
the following USP formula:
tan(α)=height/0.5 base
= 62.5 degrees
Fig 5: Angle of repose experiment

Table: 3 Accelerated Drug Stability

1

• To characterize powder flow property for the freeze-dried formulation
2

• To determine the moisture content of the freeze-dried formulation

Hypothesis
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2-theta (deg)

Accelerated Stability Study

• To characterize crystallinity of the freeze-dried formulation
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Powder flow studies

R² = 0.9995
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• To determine stability of freeze-dried powder

Pre-mixing using a
homogenizer
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• To assess drug yield of the freeze-dried powder

• Aqueous phase: non-fat milk + water
• Oil phase: Efavirenz + MCT + span 80
• An oil/water emulsion was formed
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• To formulate a freeze-dried nanoemulsion with particle size less than 1000 nm

Methods

Intensity (cps)
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Objective

A milk based freeze-dried nanoemulsion of efavirenz with a stable drug content and a zaverage of less than 1000 nm can be prepared

Meas. data:EfavirenzF1/Data 1

Meas. data:Efavirenz/Data 1
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Absorbance

• Approximately 1.8 million children under 15 years of age are living with HIV (c.2017)
• Pediatric patients with HIV have been lagging behind adults in receiving anti-retroviral
therapy (ART) due to numerous barriers, one of which being the lack of appropriate
pediatric anti-retroviral (ARV) drug formulations
• Efavirenz (EFV) is an HIV-1 specific and a first choice anti-retroviral in adults and
pediatric pharmacotherapy
• The available efavirenz formulations for pediatric patients older than 3 months are
Sustiva tablet (600 mg) and capsule (50 mg, 200 mg)
• These formulations are “Pediatric” not necessarily “Pediatric friendly”
• Therefore, there is a need to formulate a product that is easy to administer to pediatric
patients and contains natural and minimum excipients
• The freeze-dried efavirenz o/w nanoemulsion contains milk as the aqueous phase,
medium chain triglyceride as the oil phase and span 80 was added to improve the
homogeneity of the nanoemulsion
• The efavirenz freeze-dried powder will be suitable to administer by dissolving in water
or milk-based drinks or sprinkled on food for oral administration in pediatric patients
three months of age or older.

Powder X-Ray Diffraction

Drug yield: 6 days
Batch 1
Batch 2
97.8%
90.8%
Drug yield: 17 days
89.5%
104.9%
Particle size (Z-average): 6 days
604.9
561.8
Particle size (Z-average): 17 days
597.1
442.6

Batch 3
94.9%

Average
94.5%

95.6%

96.7%

576.1

580.93

502.0

513.9
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Fig 2: HPLC analysis of freeze-dried powder

Conclusion

Particle size
Table: 2 Particle size distribution of EFV freeze-dried reconstituted
nanoemulsion (d.nm)
Sample name
PDI
D(n)10
D(n)50
D(n)90
Z-Ave
Batch 1
663.5
0.605
294
381
505
Batch 2
618.6
0.490
281
364
478
Batch 3
526.8
0.562
69.6
89.4
244

• An amorphous final powder formulation was obtained by freeze-drying the nanoemulsion
• Drug yield obtained was within the FDA limit of 90-110%
• The powder could be reconstituted with water to give a nanoemulsion with mean
hydrodynamic diameter less than 1000 nm
• The freeze-dried powder showed an average of 1.16% mass loss below 150°C
• There was no significant difference in the drug content from day 0 to day 17; p-value was

Thermogravimetric Analysis
Ultrasonication

Freeze-drying

• The particle size of the emulsion was reduced
to form a nanoemulsion

The 3 batches of freeze-dried powder showed an average of 1.16% desolvation mass loss
below 150 °C

0.4983 > 0.05
• The stability testing results showed that the particle size was less than 1000 nm
• According to the USP <1174>, the powder flow was ‘very poor’

• The nanoemulsion was freeze-dried for ~ 40
hours to form the final formualtion
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